David Mersky, NOHO's CEO stated, "Today, we are announcing that the company has acquired the exclusive rights to an FDA registered medicine that will be manufactured as a new NOHO product for the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space as the product is backed by two published clinical studies."